Exact Mass: 355.9983
Exact Mass Matches: 355.9983
Found 71 metabolites which its exact mass value is equals to given mass value 355.9983,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Silver sulfadiazine
D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06B - Chemotherapeutics for topical use > D06BA - Sulfonamides C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides
(+)-Chebulic acid
(+)-Chebulic acid is found in fruits. (+)-Chebulic acid is isolated from Phyllanthus emblica (emblic). Isolated from Phyllanthus emblica (emblic). (+)-Chebulic acid is found in fruits.
O1-(4-Chlorobenzoyl)-2-[(2-furylmethyl)sulfonyl]ethanehydroximamide
9-(toluene-4-sulfonyloxy)-furo[3,2-g]chromen-7-one
2-butanoyl-3,6,8-trihydroxy-1,4-naphthoquinone 6-O-sulfate
Chebulic_acid
Chebulic acid is a natural product found in Terminalia chebula, Terminalia citrina, and Phyllanthus emblica with data available. Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity, which breaks the cross-links of proteins induced by advanced glycation end-products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress and renal damage, supporting its beneficial effect in diabetic nephropathy[1][2]. Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity, which breaks the cross-links of proteins induced by advanced glycation end-products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress and renal damage, supporting its beneficial effect in diabetic nephropathy[1][2].
(+)-Chebulic acid
3-(4-Bromobenzyl)-2-butyl-4-chloro-1H-imidazol-5-ylmethanol
4-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-3-iodobenzoic acid
2,6-Bis(methylthio)-3,5-diphenyl-4H-thiopyran-4-one
2-[(1,3-dioxoisoindol-2-yl)disulfanyl]isoindole-1,3-dione
[(3,5,6-trichloro-2-pyridyl)oxy]acetic acid, compound with triethylamine (1:1)
5-(6-CHLORO-3-PYRIDYL)-4-[3-(TRIFLUOROMETHYL)PHENYL]-4H-1,2,4-TRIAZOLE-3-THIOL
5-(CHLOROMETHYL)-3-[3,5-DI(TRIFLUOROMETHYL)STYRYL]-1,2,4-OXADIAZOLE
5-(BENZOTHIAZOL-2-YLSULFANYLMETHYL)-4-PHENYL-4H-[1,2,4]TRIAZOLE-3-THIOL
sodium bis(2-hydroxyethyl) 5-sulphonatoisophthalate
Sulfabrom
C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent
5-broMo-3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde
2-[5-iodo-3-(phenylmethoxymethyl)imidazol-4-yl]acetaldehyde
2-[2-(ALLYLOXY)-1,1,2,2-TETRAFLUOROETHOXY]TETRAFLUOROETHANESULFONYL FLUORIDE
Acetic acid,2-mercapto-, 1,1-[2-ethyl-2-[[(2-mercaptoacetyl)oxy]methyl]-1,3-propanediyl]ester
(S)-3,4-Dihydro-4-hydroxy-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
MANGANESE, CHLORO[[2,2-[1,2-ETHANEDIYLBIS[(NITRILO-KN)METHYLIDYNE]]BIS[PHENOLATO-KO]](2-)]-, (SP-5-13)-
Chlorisondamine
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C66886 - Nicotinic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D005730 - Ganglionic Blockers D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
5-bromo-2-methoxy-N-(3-methyl-2-pyridinyl)benzenesulfonamide
2-(4-(4-Hydroxyphenoxy)-3-iodophenyl)ethanaminium chloride
3-[1-(2,4-Dichlorophenyl)sulfonyl-2-pyrrolidinyl]pyridine
3-[3-(2,4-Dichlorophenoxy)propoxy]-6-methyl-2-nitropyridine
N-[2-chloro-5-(trifluoromethyl)phenyl]-5-pyridin-4-yl-1,3,4-thiadiazol-2-amine
1-[4-(3-Chloro-2,4,6-trifluorophenyl)sulfonyl-1-piperazinyl]ethanone
3-bromo-4-methyl-N-[(2-oxolanylmethylamino)-sulfanylidenemethyl]benzamide
CTPI-2
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity[1][2].
